PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma.

Abstract YM155, a small molecule inhibitor of survivin, has been studied in many tumors. It has been shown that YM155 inhibited oral squamous cell carcinoma through promoting apoptosis and autophagy and inhibiting proliferation. It was found that YM155 also inhibited the oral squamous cell carcinoma-mediated angiogenesis through the inactivation of the mammalian target of rapamycin pathway. Rapamycin, a mammalian target of rapamycin inhibitor, played an important role in the proliferation and angiogenesis of oral squamous cell carcinoma cell lines. In our study, cell proliferation assay, transwell assay, tube formation assay, and western blot assay were used to investigate the synergistic effect of rapamycin on YM155 in oral squamous cell carcinoma. Either in vitro or in vivo, rapamycin and YM155 exerted a synergistic effect on the inhibition of survivin and vascular endothelial growth factor through mammalian target of rapamycin pathway. Overall, our results revealed that low-dose rapamycin strongly promoted the sensitivity of oral squamous cell carcinoma cell lines to YM155.
PMID
Related Publications

YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.

Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.

Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.

Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.

Authors

Mayor MeshTerms
Keywords

Rapamycin

YM155

angiogenesis

oral squamous cell carcinoma

proliferation

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28618939
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170622
LR  - 20170622
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 
      in oral squamous cell carcinoma.
PG  - 1010428317706213
LID - 10.1177/1010428317706213 [doi]
AB  - YM155, a small molecule inhibitor of survivin, has been studied in many tumors.
      It has been shown that YM155 inhibited oral squamous cell carcinoma through
      promoting apoptosis and autophagy and inhibiting proliferation. It was found that
      YM155 also inhibited the oral squamous cell carcinoma-mediated angiogenesis
      through the inactivation of the mammalian target of rapamycin pathway. Rapamycin,
      a mammalian target of rapamycin inhibitor, played an important role in the
      proliferation and angiogenesis of oral squamous cell carcinoma cell lines. In our
      study, cell proliferation assay, transwell assay, tube formation assay, and
      western blot assay were used to investigate the synergistic effect of rapamycin
      on YM155 in oral squamous cell carcinoma. Either in vitro or in vivo, rapamycin
      and YM155 exerted a synergistic effect on the inhibition of survivin and vascular
      endothelial growth factor through mammalian target of rapamycin pathway. Overall,
      our results revealed that low-dose rapamycin strongly promoted the sensitivity of
      oral squamous cell carcinoma cell lines to YM155.
FAU - Li, Kong-Liang
AU  - Li KL
AD  - 1 Department of Oral and Maxillofacial Surgery, Peking University Shenzhen
      Hospital, Shenzhen, China.
FAU - Wang, Yu-Fan
AU  - Wang YF
AD  - 1 Department of Oral and Maxillofacial Surgery, Peking University Shenzhen
      Hospital, Shenzhen, China.
FAU - Qin, Jia-Ruo
AU  - Qin JR
AD  - 2 Department of Stomatology, Tenth People's Hospital of Tongji University,
      Shanghai, China.
FAU - Wang, Feng
AU  - Wang F
AD  - 1 Department of Oral and Maxillofacial Surgery, Peking University Shenzhen
      Hospital, Shenzhen, China.
FAU - Yang, Yong-Tao
AU  - Yang YT
AD  - 1 Department of Oral and Maxillofacial Surgery, Peking University Shenzhen
      Hospital, Shenzhen, China.
FAU - Zheng, Li-Wu
AU  - Zheng LW
AD  - 3 Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.
FAU - Li, Ming-Hua
AU  - Li MH
AD  - 4 Central Laboratory, Peking University Shenzhen Hospital, Shenzhen, China.
FAU - Kong, Jie
AU  - Kong J
AD  - 5 Department of Stomatology, Shenzhen Children's Hospital, Shenzhen, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - 6 Biomedical Research Institute, Shenzhen Peking University-The Hong Kong
      University of Science and Technology Medical Center, Shenzhen, China.
FAU - Yang, Hong-Yu
AU  - Yang HY
AD  - 1 Department of Oral and Maxillofacial Surgery, Peking University Shenzhen
      Hospital, Shenzhen, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Imidazoles)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Naphthoquinones)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (YM 155)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Imidazoles/*administration & dosage
MH  - Inhibitor of Apoptosis Proteins/biosynthesis
MH  - Mice
MH  - Mouth Neoplasms/*drug therapy/pathology
MH  - Naphthoquinones/*administration & dosage
MH  - Neovascularization, Pathologic/*drug therapy/pathology
MH  - Sirolimus/*administration & dosage
MH  - Vascular Endothelial Growth Factor A/biosynthesis
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Rapamycin
OT  - YM155
OT  - angiogenesis
OT  - oral squamous cell carcinoma
OT  - proliferation
EDAT- 2017/06/18 06:00
MHDA- 2017/06/24 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317706213 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317706213. doi: 10.1177/1010428317706213.